Keros Therapeutics, Inc.(KROS) Stock Research - Grey Stern Research
Loading...

Keros Therapeutics, Inc. (KROS) Stock Analysis

$68.15 (0.35%)

KROS Financial Performance


Use the table below to view Keros Therapeutics, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q2 - 2024

Metric Value Ranking among Peers
Price $68.15 -
52 Week Low $27.31 -
52 Week High $73.00 -
Market Cap $2.8 Billion 4/20
Gross Margin -100% 17/20
Profit Margin -100% 13/20
EBITDA margin -135495% 20/20
Q2 - 2024 Revenue $37,000 11/20
Q2 - 2024 Earnings -$45.3 Million 14/20
Q2 - 2024 Free Cash Flow -$40.1 Million 18/20
Trailing 4 Quarters Revenue $271,000 14/20
Trailing 4 Quarters Earnings -$168.1 Million 17/20
Quarterly Earnings Growth -21% 12/20
Annual Earnings Growth -24% 14/20
Quarterly Revenue Growth 0% 6/20
Annual Revenue Growth 0% 6/20
Cash On Hand $405.9 Million 1/20
Short Term Debt $1.1 Million 13/20
Long Term Debt $12.9 Million 11/20

Keros Therapeutics, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Keros Therapeutics, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 3/20
PS 10186.64 1/20
PB 6.56 3/20
PC 6.80 7/20
Liabilities to Equity 0.08 16/20
ROA -0.37 10/20
ROE -0.40 7/20
Current Ratio 13.34 4/20
Quick Ratio 11.90 4/20
Long Term Debt to Equity 0.03 11/20
Debt to Equity 0.03 13/20
Burn Rate 8.81 1/20
Cash to Cap 0.15 13/20
CCR 0.89 6/20
EV to EBITDA -47.25 19/20
EV to Revenue 8740.49 1/20

Company Details

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

CEO: Dr. Jasbir Seehra

Website: https://www.kerostx.com

Address: 99 Hayden Ave Ste 120 (Bld E Lexington, MASSACHUSETTS

Exchange: NASDAQ Global Market

Industry: Biotechnology

Keros Therapeutics, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Keros Therapeutics, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
AnaptysBio, Inc. ANAB $681.6 Million
Syndax Pharmaceuticals, Inc. SNDX $1.9 Billion
Fennec Pharmaceuticals Inc. FENC $116.6 Million
Homology Medicines, Inc. FIXX $3.0 Million
IDEAYA Biosciences, Inc. IDYA $2.8 Billion
Kezar Life Sciences, Inc. KZR $54.3 Million
MeiraGTx Holdings plc MGTX $549.5 Million
NGM Biopharmaceuticals, Inc. NGM $128.5 Million
Replimune Group, Inc. REPL $854.0 Million
Larimar Therapeutics, Inc. LRMR $592.8 Million
Harmony Biosciences Holdings, Inc. HRMY $2.0 Billion
Edgewise Therapeutics, Inc. EWTX $3.3 Billion
Monte Rosa Therapeutics, Inc. GLUE $614.3 Million
Aerovate Therapeutics, Inc. AVTE $75.9 Million
Bolt Biotherapeutics, Inc. BOLT $24.3 Million
Century Therapeutics, Inc. IPSC $125.0 Million
Erasca, Inc. ERAS $878.6 Million
Janux Therapeutics, Inc. JANX $2.8 Billion
Surrozen, Inc. SRZN $31.7 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
KROS Income Statements
Quarter Year Revenue Earnings
Q2 2024 $ 37,000 -$45.3 Million
Q1 2024 $ 83,000 -$43.1 Million
Q4 2023 $ 143,000 -$40.2 Million
Q3 2023 $ 8,000 -$39.4 Million
Q2 2023 $ 0 -$37.5 Million
Q1 2023 $ 0 -$32.7 Million
Q4 2022 $ 0 -$29.7 Million
Q3 2022 $ 0 -$23.5 Million

View All

KROS Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2024 $405.9 Million $455.0 Million $14.0 Million $420.9 Million
Q1 2024 $442.4 Million $485.8 Million $14.2 Million $453.9 Million
Q4 2023 $331.1 Million $370.0 Million $14.4 Million $332.2 Million
Q3 2023 $287.9 Million $326.2 Million $14.3 Million $295.8 Million
Q2 2023 $322.0 Million $356.3 Million $14.0 Million $326.3 Million
Q1 2023 $351.4 Million $384.4 Million $14.0 Million $355.0 Million
Q4 2022 $279.0 Million $306.8 Million $13.3 Million $277.4 Million
Q3 2022 $239.4 Million $252.6 Million $455,000 $241.0 Million

View All

KROS Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q2 2024 -$40.1 Million -$310,000 -$36.6 Million
Q1 2024 -$45.5 Million -$946,000 $111.3 Million
Q4 2023 -$26.0 Million -$541,000 $43.3 Million
Q3 2023 -$34.5 Million -$550,000 -$34.2 Million
Q2 2023 -$31.1 Million -$311,000 -$29.4 Million
Q1 2023 -$35.3 Million -$1.1 Million $72.4 Million
Q4 2022 -$21.8 Million -$351,000 $39.6 Million
Q3 2022 -$49.5 Million -$890,000 $23.8 Million

View All